Iran War Pushes Essential Drug Prices Up 3-5%

Essential drug prices in Iran could rise by 3-5% in the near term as war-related disruptions push up input costs, according to industry estimates. The increase would effectively reverse the gains consumers saw from late-September cuts in GST rates, resetting prices to pre-cut levels. The mechanism is straightforward: supply chain stress on raw material and active pharmaceutical ingredient costs feeds directly into retail drug pricing, with limited ability to absorb margin compression in a sector already operating on thin spreads. Industry expects the price increase to hold for 3-4 months, contingent on when input cost pressures ease. A rollback is factored into the outlook if and when supply conditions normalize. The critical variable is duration: a prolonged conflict would extend the repricing window beyond current forecasts and potentially trigger more structural adjustments in sourcing. Buyers and procurement teams should track input cost indices and any regulatory guidance on price controls, which could cap or defer retail pass-through.